Events | 2022.10.11
Leveraging Clinical Trial Ready IHC Assays from Target Validation to Prospective Enrollment and CDx Development, Upcoming Webinar Hosted by Xtalks
In this free webinar, Dr. Frank Lynch, Discovery Life Sciences, will discuss why successful drug development studies often begin and end with high quality immunohistochemistry (IHC) biomarker assays. Attendees will gain insights into Discovery’s approach to validating target expression using immunohistochemistry (IHC) assays, a critical step toward cancer drug development. Dr. Lynch will explain how sound, strategic decisions around target expression can be made quickly based on reliable IHC biomarker data, from performing translational studies through to prospectively screening patients into clinical studies designed to increase the likelihood of patient response.
(PRWeb October 11, 2022)
Read the full story at https://www.prweb.com/releases/leveraging_clinical_trial_ready_ihc_assays_from_target_validation_to_prospective_enrollment_and_cdx_development_upcoming_webinar_hosted_by_xtalks/prweb18946062.htm
For more information, please visit
https://www.prweb.com/releases/leveragin[...]ed_by_xtalks/prweb18946062.htm
